Found: 14
Select item for more details and to access through your institution.
Genomic characteristics and prognostic significance of co‐mutated ASXL1/SRSF2 acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 4, p. 462, doi. 10.1002/ajh.26110
- By:
- Publication type:
- Article
A Comparison of Clofarabine-based (GCLAC) and Cladribine-based (CLAG) Salvage Chemotherapy for Relapsed/Refractory AML.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Phase I Clinical Trials in Acute Myeloid Leukemia: 23-Year Experience From Cancer Therapy Evaluation Program of the National Cancer Institute.
- Published in:
- 2016
- By:
- Publication type:
- journal article
A reappraisal of ASXL1 mutation sites and the cohesin-binding motif in myeloid disease.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00876-w
- By:
- Publication type:
- Article
A reappraisal of ASXL1 mutation sites and the cohesin-binding motif in myeloid disease.
- Published in:
- 2023
- By:
- Publication type:
- Letter
A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Myeloid sarcoma manifesting as generalized lymphadenopathy in a patient with myelofibrosis.
- Published in:
- Clinical Case Reports, 2019, v. 7, n. 11, p. 2274, doi. 10.1002/ccr3.2473
- By:
- Publication type:
- Article
Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options.
- Published in:
- Current Hematologic Malignancy Reports, 2021, v. 16, n. 1, p. 97, doi. 10.1007/s11899-021-00608-6
- By:
- Publication type:
- Article
Venetoclax‐induced tumour lysis syndrome in acute myeloid leukaemia.
- Published in:
- British Journal of Haematology, 2020, v. 188, n. 1, p. 173, doi. 10.1111/bjh.16235
- By:
- Publication type:
- Article
Response to Tyrosine Kinase Inhibitors in Real-World Patients With Chronic Myeloid Leukemia.
- Published in:
- Annals of Pharmacotherapy, 2022, v. 56, n. 7, p. 753, doi. 10.1177/10600280211044160
- By:
- Publication type:
- Article
The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?
- Published in:
- Therapeutic Advances in Hematology, 2022, v. 13, p. 1, doi. 10.1177/20406207221112899
- By:
- Publication type:
- Article
Clinical and molecular features of FLT3 juxtamembrane domain missense mutations in acute myeloid leukaemia.
- Published in:
- Journal of Cellular & Molecular Medicine, 2022, v. 26, n. 24, p. 6079, doi. 10.1111/jcmm.17608
- By:
- Publication type:
- Article
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 1, p. 105, doi. 10.1007/s00277-023-05552-4
- By:
- Publication type:
- Article
Hypomethylating agents super-responders: challenging the dogma of long-term remission for acute myeloid leukemia.
- Published in:
- 2020
- By:
- Publication type:
- case study